Healthcare Jan 06, 2022 09:28 AM (GMT+8) · EqualOcean
Jiangsu new element Pharmaceutical Technology Co., Ltd. recently completed a round C financing of more than 300 million yuan. This round of financing is led by Xicheng Jinrui and gaotejia, followed by Yifeng capital, Yuanhe holdings and Qiandao group, and the original shareholders Kaitai capital, Lizhu pharmaceutical and Sequoia China continue to make additional investment. Previously, new element medicine has completed a total financing of hundreds of millions of yuan. The round C financing fund will be mainly used to complete the global phase 3 clinical of abp-671 and the preclinical and early clinical research of other pipeline products.